Abstract: The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks.

Abstract: Lowering total cholesterol and improving of blood lipid spectrum composition as seen in a decrease of low and very low density lipoprotein levels, triglycerides and Lipoprotein a, and an increase in high density lipoproteins through taking fumarate and/or fumarates and B vitamins. The fumarate is any of fumaric acid, neutral or acidic sodium fumarate, potassium fumarate, ammonium fumarate, fumarate of a general formula Fum-Me-Fum.nH2O, where Fum—fumaric acid anion, Me—zinc, calcium or magnesium, n=0-8 or mixture of these. The B group can be B12, B6, B2, preferably, at least two of these. Preferably also including at least one amino acid from the following: glycine, L-glutamic acid and/or its salts, L-arginine and/or its salts, L-carnitine and/or its salts, asparagine and/or its salts. Preferably also succinic, citric or isocitric acid and/or their salts. Preferably also including other vitamins, fillers, ballast substances, flavors, colors, sugars, oils.

Abstract: The present invention relates to the therapeutic use of acylated piceid derivative compounds in ocular pathologies, in particular retinitis pigmentosa and in age-related macular degeneration.

Abstract: Provided is a solubilization enhancer for pyrroloquinoline quinone or a salt thereof in an aqueous solvent, comprising resistant dextrin as an active ingredient.

Abstract: The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.

Abstract: The present invention discloses a functionalized hyaluronic acid or a derivative thereof, as well as a process for the preparation thereof, and the use thereof as a biomaterial and as an ingredient in pharmaceutical compositions. The present invention furthermore discloses the use of said functionalized hyaluronic acid or a derivative thereof in the treatment of pathologies ascribable to altered galectin expression.

Abstract: The present invention discloses a branched polyethylene glycol epoxy derivative crosslinked sodium hyaluronate gel, preparation and application thereof. The crosslinking agent used in the crosslinked sodium hyaluronate gel prepared by the present invention is a polyethylene glycol epoxy derivative, due to the existence of multiple ether bonds in the molecule of the crosslinking agent, there are more hydrogen bonds in the gel system; meanwhile, due to the particularity of the space structure of the branched polyethylene glycol epoxy derivative, the gel prepared has a more complex winding structure in its space, thus achieving better stability. Moreover, the branched polyethylene glycol epoxy derivative involved in the present invention is a compound with single molecular weight, therefore, the gel prepared thereby has better batch stability.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.

Abstract: Various embodiments disclosed herein include methods of modulating the function of Zinc Activated Cation Channel (ZACN) in a subject comprising: administering to the subject a pharmaceutically effective dosage of ATP, a purinergic compound, red or blue dye, heparin or heparin analog, desipramine, reboxetine, and/or tomoxetine; and modulating the function of ZACN in the subject. Various embodiments disclosed herein also include methods of treating a disease in a subject comprising: administering to the subject a pharmaceutically effective dosage of a compound capable of modulating the function of the Zinc Activated Cation Channel (ZACN), and treating the disease.

Abstract: The present invention relates to nutritional compositions for infants or young children and their health effects, that comprise at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide. These nutritional compositions are for use to prevent and/or treat infection in an infant or young child, by promoting and/or reducing specific microbiota communities in an infant or young child.

Abstract: A polymer composition can include an aqueous vehicle and a temperature-responsive degradable polymer having a polymer including a LCST-imparting unit and a lactone-bearing unit including a pendent lactone group. The number of LCST-imparting units is greater than the number of lactone-bearing units. The temperature-responsive degradable polymer has an initial lower critical solution temperature (LCST) of 37° C. or below. The polymer composition can have a pH lower than 7.

Abstract: The present invention relates to a composition for preventing or treating a neurological disorder, comprising aucubin. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating mental illness, comprising aucubin or a pharmaceutically acceptable salt thereof as an active ingredient, to a food composition, to a method for treating mental illness, and to a composition for maintaining the survival of GABAergic neurons, promoting the regeneration of GABAergic neurons, or preventing the apoptosis of GABAergic neurons. The aucubin according to the present invention exhibits effects of maintaining the survival of GABAergic neurons, promoting the regeneration of GABAergic neurons, preventing the apoptosis of GABAergic neurons, and promoting the production of GABA which is a neurotransmitter, and thus, the aucubin can be effectively used in the prevention or treatment of mental illnesses such as ADHD or autism, etc, which are caused by the deficiency of GABAergic neurons.

Abstract: The present invention discloses a pharmaceutical use of argininyl fructosy glucose (AFG), and belongs to the field of research and development of pharmaceutical products. The pharmaceutical use refers to application of the AFG as an active ingredient in preparation of a drug for treating or preventing an acute hepatic failure disease (AHFD). The AHFD is an oxidative stress injury caused by use of a combination of lipopolysaccharide (LPS) and D-galactosamine (D-GalN), and the drug is used for protecting liver cells from injuries, and reducing apoptosis caused by LPS/D-GalN. The purity of the AFG is 80%-99.99%. The present invention proposes the use of the AFG in prevention or treatment of the acute hepatic failure for the first time, which provides a new raw material for the preparation of the drug for the acute hepatic failure, and also provides a new method for the prevention and treatment of the acute liver failure.

Abstract: A nutritional composition for use in providing a neuroprotective effect to an individual in need thereof which nutritional composition comprises at least one human milk oligosaccharide selected from lacto-N-neotetraose and 2?-fucosyllactose.

Abstract: The invention is directed to a simple and economical method for producing nanocrystalline cellulose from microcrystalline cellulose by contacting frozen concentrated sulfuric acid with microcrystalline cellulose, diluting the mixture in water and hair-shaped ice to hydrolyze the microcrystalline cellulose, and separating the NCC. Another aspect of the invention pertains to an apparatus for conducting this method which includes an acid resistant hydrolysis container having a cooling jacket containing a hollow stirrer each of which may be filled with liquid nitrogen.

Abstract: The invention provides compositions and methods to treat diabetic neuropathies. In particular, the invention provides combinations of at least two types of antioxidants have complementary effects for use against diabetic neuropathies. The two types of antioxidants include: antioxidants that comprise stabilizing heteroatoms and antioxidants with extended conjugated segments in a ring structure. At least one of each type of provided antioxidant has a pro-oxidative or conditionally pro-oxidative effect.

Abstract: There is provided a composition comprising: A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and/or phosphoserine; B) N-acetyl cysteine, cysteine and/or cystine; C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4-trimethylammoniobutanal, 3-hydroxy-N6,N6,N6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and/or lysine; and D) nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate ribonucleoside, nicotinamide and/or nicotinate, wherein the molar ratio of A) to D) is between 250:1 and 1.5:1 and the molar ratio of A) to B) is between 16:1 and 1:4. The composition may be used in a method of treatment of a medical condition selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), type 2 diabetes, obesity, insulin resistance and dyslipidemia.

Abstract: Provided are methods for prophylaxis or treatment of SARS-CoV-2 by administering a composition comprising one or more iminosugars to an individual in need thereof. The compositions may be administered to an individual who is at risk of becoming infected by SARS-CoV-2, or has been diagnosed with a SARS-CoV-2 infection. The iminosugars can inhibit SARS-CoV-2 cell entry and replication. The iminosugars potentiate co-administered antiviral agents, such as nucleoside analogs.

Abstract: A method for preventing or mitigating an acute allergic response in a subject is disclosed. The method includes a step of administering a nutritional composition to the subject. The nutritional composition includes at least one of an acidic or a neutral HMO, but does not include an N-acetyl-lactosamine.

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.